Preclinical evidence finds no stable CBD dose-response for fear

Can a generalizable dose-effect relationship be inferred for cannabidiol? Evidence from the preclinical literature.

Psychopharmacology • • Review • Highly Relevant
🤖

AI Summary

This study asked whether preclinical research supports a consistent relationship between CBD dose and changes in anxiety- and fear-related behavior. The authors used regression analyses to examine effect sizes from 312 experiments in mice and rats, considering anxiety and conditioned-fear outcomes separately and together, and comparing raw with allometrically adjusted doses. This was an analysis of animal studies, not a human clinical trial.

Intermediate systemic doses were more often linked to larger reductions in aversive behavior, but that pattern did not hold consistently across species or behavioral domains. Some analyses suggested nonlinear relationships, while pooled, allometrically adjusted analyses favored linear models; overall, the literature did not support a stable, generalizable CBD dose-effect relationship. The findings may reflect substantial differences in study methods and CBD’s pharmacological complexity. Because this abstract-based summary describes a synthesis of varied preclinical experiments, it cannot establish a dose response in people or determine an effective dose; the authors call for more controlled, balanced factorial studies.

💡 Key Findings

1
Across 312 mouse and rat experiments, the preclinical literature did not support a stable, generalizable CBD dose-effect relationship for anxiety- and fear-related behavior.
High
90%
2
Intermediate systemic CBD doses were more often associated with larger antiaversive effects, but the trend did not hold across species or behavioral domains.
High
90%
3
In conditioned-fear analyses, species significantly moderated the dose-effect relationship; sex, stress history, treatment regimen, age, and treatment-testing interval were not significant moderators.
High
85%
4
The authors identify methodological heterogeneity and possible pharmacological complexity as explanations, and conclude that more controlled factorial studies are needed to improve reproducibility and understanding.
High
90%

📄 Original Abstract

RATIONALE: Cannabidiol (CBD) modulates anxiety and fear in rodents; however, the dose-dependent characteristics of these effects remain unclear. OBJECTIVES & METHODS: Regression-based analyses assessed how consistent dose-effect inferences are across diverse studies and determined whether linear or nonlinear models best describe the relationship between CBD dose and behavioral outcomes. Hedges' g effect sizes from 312 experiments in mice and rats were analyzed separately and in pooled datasets, using both raw and allometrically normalized doses. We also evaluated how biological and procedural variables moderated dose-effect relationships. RESULTS: Intermediate doses of systemic CBD administration were more often associated with larger antiaversive effect sizes; however, this trend did not hold across species or behavioral domains. Some analyses showed nonlinear trends, primarily associated with high-dose observations. After allometric scaling and pooling of anxiety and conditioned fear datasets, linear models fit better than nonlinear models. Analyses of pooled and anxiety datasets revealed no significant moderators of the dose-effect relationship. In contrast, analyses limited to conditioned fear identified species as a significant moderator, while sex, stress history, treatment regimen, age, and treatment-testing interval were not significant. CONCLUSIONS: These findings indicate that the preclinical literature does not support a stable or generalizable CBD dose-effect function. The observed relationships likely reflect substantial methodological heterogeneity and may also reflect CBD's pharmacological complexity. Factorial studies with balanced dose distributions and controlled experimental conditions are necessary to improve reproducibility and mechanistic understanding of CBD's antiversive effects.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.